Literature DB >> 12379629

Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.

B Bresnihan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379629      PMCID： PMC1766718          DOI： 10.1136/ard.61.suppl_2.ii74

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

Review 1.  The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1.

Authors:  C A Dinarello
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

2.  A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.

Authors:  Y Jiang; H K Genant; I Watt; M Cobby; B Bresnihan; R Aitchison; D McCabe
Journal:  Arthritis Rheum       Date:  2000-05

3.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Stanley Cohen; Eric Hurd; John Cush; Michael Schiff; Michael E Weinblatt; Larry W Moreland; Joel Kremer; Moraye B Bear; William J Rich; Dorothy McCabe
Journal:  Arthritis Rheum       Date:  2002-03

Review 4.  Anti-interleukin-1 therapy in rheumatic diseases.

Authors:  J M Dayer; U Feige; C K Edwards ; D Burger
Journal:  Curr Opin Rheumatol       Date:  2001-05       Impact factor: 5.006

5.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Authors:  B Bresnihan; J M Alvaro-Gracia; M Cobby; M Doherty; Z Domljan; P Emery; G Nuki; K Pavelka; R Rau; B Rozman; I Watt; B Williams; R Aitchison; D McCabe; P Musikic
Journal:  Arthritis Rheum       Date:  1998-12

6.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06

7.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02
  7 in total
  4 in total

Review 1.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.

Authors:  Annamaria Iagnocco; Chiara Perella; Esperanza Naredo; Gary Meenagh; Fulvia Ceccarelli; Emanuela Tripodo; Stefania Basili; Guido Valesini
Journal:  Clin Rheumatol       Date:  2007-10-19       Impact factor: 2.980

3.  Induction of vascular endothelial growth factor and matrix metalloproteinase-3 (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes.

Authors:  Kenji Inoue; Kayo Masuko-Hongo; Masahiro Okamoto; Kusuki Nishioka
Journal:  Rheumatol Int       Date:  2004-09-29       Impact factor: 2.631

4.  The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.

Authors:  Gaby Palmer; Danielle Burger; Françoise Mezin; David Magne; Cem Gabay; Jean-Michel Dayer; Pierre-André Guerne
Journal:  Arthritis Res Ther       Date:  2004-02-19       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.